Mesoblast shares (ASX: MSB) put up a solid recovery today, with the stock climbing 5.68% to close at A$1.86, fresh off 52-week lows of A$1.74. Today’s ASX 200 leading performance will be welcome news for holders who have seen shares tumble over the past three months.
The bounce lifted Mesoblast out from oversold technical territory, with its RSI recovering from 29 to 39.3 by the close. Despite today’s move, the Mesoblast share price remains 6.5% lower week-to-date, and down 36% over the past three months leading in. Whilst this looks like a technical bounce at this stage, recent financials may provide some further support in the weeks and months ahead.
The Latest Look
Ryoncil Revenue Acceleration
Mesoblast’s flagship product, Ryoncil (remestemcel-L-rknd), the only FDA-approved cell therapy for pediatric steroid-refractory acute graft-versus-host disease (SR-aGVHD), reported quarterly gross sales growth of more than 37% quarter-on-quarter in its most recent operational update. The company recorded its highest number of new patient starts in September, rebounding strongly from a seasonal summer lull that had weighed on earlier quarterly figures.
Alongside the revenue improvement, net operating cash burn fell sharply, driven by rising customer receipts and tightly managed clinical expenditure. For a company that has historically drawn criticism for its cash consumption rate, the combination of accelerating revenue and reduced burn is a meaningful shift in the financial narrative.
FDA Approval for New Potency Assay
The US Food and Drug Administration approved Mesoblast’s proprietary T-Cell Proliferation Inhibition BioAssay, known as TIBA, for use in release and stability monitoring of all new commercial Ryoncil batches. While the approval of a quality control assay may appear to be a technical, behind-the-scenes milestone, its commercial significance should not be underestimated.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The TIBA approval validates Mesoblast’s Chemistry, Manufacturing, and Controls framework and removes a potential regulatory bottleneck that could otherwise constrain manufacturing scale-up or complicate future facility transfers.
Balance Sheet Restructuring
Perhaps the most structurally significant recent development is Mesoblast’s completion of a US$125 million, five-year non-dilutive debt facility arranged with shareholder and board member Dr. Gregory George.
An initial US$75 million drawdown was used to retire the existing NovaQuest debt facility, which carried higher costs and more restrictive covenants. The new facility is fixed at 8% per annum interest and carries no immediate equity dilution, a critical feature given that the prospect of heavily discounted capital raises has historically been one of the most persistent overhangs on MSB shares.
What Lay Ahead
The technical picture for Mesoblast is only mildly improved, with the share price continuing to sit below the 30 day, 50, and 200 day SMAs in a clearly bearish trend. The RSI recovering from 29 toward 40 suggests the worst of the oversold selling pressure may be abating, though this can also be a sign of technicals cooling off for a continuation trade. Momentum is not in the bull camp, although there is a support zone between A$1.75-A$1.80 that had previously acted as resistance back in mid 2025, and in 2024 prior to the breakout.
Volume was slightly lower than the recent average, with 4.56million shares changing hands ~ 12% below the ADV. Many of those looking to exit may have already done so. Mesoblast’s rebound reflects a market working through the latest update, alongside the persistent execution risk and short-seller pressure that have taken hold in recent months. Whether the A$1.74 low marks a defendable floor or merely a pause in the broader downtrend will be told in time, with plenty of eyes on this one.
Bull Case:
- Ryoncil gross sales surged over 37% quarter-on-quarter with record September patient starts
- Non-dilutive US$125 million debt facility eliminates near-term equity dilution risk
- RSI recovering from deeply oversold 29 signals potential technical floor at A$1.74
- FDA-approved TIBA assay removes manufacturing bottleneck for commercial scale-up
- Analysts maintain price targets implying over 100% upside from current levels
Bear Case:
- Stock remains down 36% over three months with elevated short interest still present
- Single-product commercial dependency on Ryoncil creates concentrated execution risk
- Debt-financed operations require consistent revenue growth to remain sustainable
- Pipeline assets rexlemestrocel-L carry significant clinical and regulatory uncertainty
- High-beta profile leaves MSB vulnerable to broader ASX healthcare sector selloffs
